Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

This study is testing a combination of two drugs — atezolizumab (immunotherapy) and sacituzumab govitecan (a targeted antibody-drug) — to prevent triple-negative breast cancer from coming back after surgery in patients who still had cancer remaining after neoadjuvant chemotherapy. **You may be eligible if...** - You have triple-negative breast cancer (a type that does not respond to hormone therapy or HER2-targeted therapy) - You completed chemotherapy before surgery, but cancer was still found in the breast or lymph nodes after surgery - You have not yet started additional (adjuvant) chemotherapy after surgery - You are 18 or older **You may NOT be eligible if...** - You have previously received sacituzumab govitecan, irinotecan, or similar antibody-drug treatments - You have active autoimmune disease - You are pregnant or breastfeeding - You have significant heart, liver, or lung disease Talk to your doctor to see if this trial is right for you.